Longevity Drugs in Clinical Trials: Where the Pipeline Stands
A survey of what is actually being tested in humans, why almost none of it is being tested against ageing itself, and what the endpoint problem means for how fast this field can move.
The Short Answer
There is no approved drug for ageing anywhere, and the reason is structural rather than scientific. Ageing is not a recognised indication, so a trial cannot be designed against it, which means every candidate must be developed against a specific condition instead. That constraint shapes the entire pipeline: what gets funded, what endpoints are chosen, and how long anything takes. Understanding it explains more about the field's pace than any individual compound does.
The Endpoint Problem
To license a drug you need an endpoint a regulator accepts. For ageing there are three options and none currently works.
Lifespan. Unusable. A trial would run for decades, cost beyond any sponsor's tolerance, and lose participants to every other cause in the interval.
Composite morbidity. More tractable. The proposed design for a metformin trial in ageing uses time to a first event among several age-related conditions, which is why that trial matters as a regulatory precedent as much as a scientific one.
Surrogate biomarkers. Attractive and unvalidated. No ageing biomarker has been accepted as a surrogate endpoint, because acceptance requires demonstrating that changing the marker changes outcomes, which nobody has done.
Until one of these is resolved, development proceeds disease by disease. That is not necessarily bad science, and it does mean that a compound with broad ageing effects gets tested narrowly, and its label reflects the narrow indication rather than the broad mechanism.
What Is Actually in Human Trials
| Agent or class | Indication being tested | Stage |
|---|---|---|
| Metformin | Composite age-related morbidity, plus several specific conditions | Trial designed; funding and progress have been slow |
| Rapamycin and rapalogs | Immune function in older adults, periodontal and cardiac measures | Small trials completed and ongoing |
| Senolytics | Pulmonary fibrosis, kidney disease, osteoarthritis, frailty, bone | Early phase, small |
| GLP-1 receptor agonists | Cardiovascular and kidney outcomes; approved for other indications | Large trials completed |
| SGLT2 inhibitors | Cardiovascular, kidney and heart failure outcomes; approved | Large trials completed |
| NAD+ precursors | Metabolic and functional measures in older adults | Small trials, inconsistent |
| Anti-inflammatory agents | Cardiovascular events via inflammatory pathways | Large trials completed for some agents |
| Thymic regeneration approaches | Immune ageing measures | Very early, small |
| Klotho and other biologics | Cognitive and kidney measures | Preclinical to very early |
The pattern worth noticing: the agents with the strongest human outcome data are approved metabolic and cardiovascular drugs, tested for cardiovascular and kidney endpoints, that happen to affect ageing-relevant biology. The agents marketed most enthusiastically as longevity compounds have the least human outcome data.
Metformin and the Precedent It Would Set
The proposed metformin trial in ageing is significant less for metformin than for the design. If a regulator accepts a composite age-related morbidity endpoint, every subsequent candidate has a route to trial that does not currently exist.
The evidence motivating it comes from observational data suggesting people with type 2 diabetes taking metformin had mortality comparable to or better than matched non-diabetic controls in some analyses. That is a striking observation and a fragile one, subject to confounding by indication, prescription patterns and healthy-user effects, which is exactly why a randomised trial is needed.
There is also a real counter-consideration. Metformin has been reported to attenuate some adaptations to exercise training, including mitochondrial and cardiorespiratory responses, in older adults. If confirmed, that would represent a direct trade-off against one of the best-evidenced interventions in the field, and it is the kind of interaction that only a trial with functional endpoints would surface.
Progress has been slow, largely because a generic drug with no commercial sponsor is difficult to fund. That funding asymmetry is itself part of why the pipeline looks the way it does.
Rapamycin: The Strongest Animal Case
Rapamycin extends lifespan in mice more reliably than any other pharmacological agent, works when started in mid or late life, and does so across genetic backgrounds and both sexes. That is a considerably stronger animal record than anything else discussed here.
The human position is different. It is an approved immunosuppressant with a known side-effect profile at transplant doses, including impaired glucose tolerance, mouth ulceration, altered lipids and infection risk. Longevity interest centres on intermittent low dosing, which is proposed to engage mTORC1 while sparing mTORC2 and thereby avoiding much of the metabolic penalty. That proposal is plausible and not established in humans.
Human trials so far have been small: improved immune response to vaccination in older adults with a rapalog, small studies of periodontal and cardiac measures, and observational reports from off-label use that cannot establish safety or benefit. What does not exist is a randomised trial of intermittent rapamycin with functional or morbidity endpoints in healthy older adults, which is the trial the field needs and has not run.
How to Read Pipeline News
Four questions handle almost every announcement in this space.
What phase, and how many participants? A 20-person open-label study is a signal to design a trial around, not a result. Phase 1 establishes tolerability, not benefit.
What was the endpoint? A biomarker moving is weaker than a function improving, which is weaker than an outcome changing. Most longevity trial news reports the first.
Was there a control group? Open-label studies in older adults are particularly susceptible to placebo and monitoring effects on the functional measures usually reported.
Who is announcing it? A press release from a company raising capital and a peer-reviewed publication are not the same document, and the first frequently precedes the second by years or indefinitely.
Applying these will deflate a large share of longevity news, which is the correct response to a field where preclinical results are routinely reported in language suited to clinical ones.
What a Realistic Decade Looks Like
The plausible near-term developments, in rough order of likelihood:
Approved metabolic and cardiovascular drugs accumulating further outcome data that is relevant to ageing without being labelled for it. This is where most of the real progress will appear, and it will not be marketed as longevity medicine.
Senolytics reaching mid-stage trials in specific conditions, with the first meaningful randomised results in a narrow indication rather than in ageing.
A validated biomarker or a composite endpoint gaining regulatory acceptance, which would be the single most consequential development because it unblocks everything else.
Reprogramming and gene-based approaches remaining preclinical for general use, with possible early trials in localised indications.
What is unlikely within a decade: an approved drug indicated for ageing, a validated intervention that extends human lifespan, or any consumer supplement acquiring outcome data comparable to the approved agents above.
For a reader the practical implication is unchanged by any of it. The interventions with human outcome data today are exercise, sleep, not smoking, metabolic health and, where clinically indicated, a small number of approved medicines. The pipeline is worth following and it does not yet contain anything that changes what to do this year.
The AEONNN Perspective
AEONNN's Regulatory layer explains the shape of this pipeline better than the Evidence layer does. Ageing is not an approved indication, so no compound is developed against it, and members will keep encountering agents whose ageing-relevant mechanism is real and whose label describes something narrower.
The Evidence layer maintains the ranking that matters: outcome data first, functional measures second, biomarkers third, mechanism last. Applied honestly, that ranking places approved cardiometabolic drugs above every marketed longevity compound, which is an uncomfortable result for the category and the correct one.
It maps to Pillar 10 and Pillar 4. The Innovation layer tracks the pipeline so the platform can say what stage something is at rather than what it might eventually do, and the most consequential thing to watch is not a compound at all. It is whether a composite morbidity endpoint gains regulatory acceptance, because that unblocks the rest.
Pillar Matrix mapping
Longevity and Biological Age, Metabolic and Cardiovascular Health
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Regulatory Layer (EFSA, FDA, EMA)
- Innovation Layer (bioRxiv preprints, patent filings)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
Is there an approved drug for aging?
No. Ageing is not a recognised indication in any major jurisdiction, so candidates must be developed against specific conditions instead.
What is the TAME trial?
A proposed randomised trial of metformin using a composite endpoint of time to a first age-related event. Its regulatory significance is at least as large as its scientific one, because it would establish a usable endpoint.
Why can’t lifespan be a trial endpoint?
A lifespan trial would run for decades, cost beyond any sponsor’s tolerance and lose participants to competing causes. No ageing biomarker has been validated as a surrogate.
What is the best-evidenced longevity drug in animals?
Rapamycin extends mouse lifespan more reliably than any other pharmacological agent, including when started in mid or late life, across genetic backgrounds and both sexes.
Does metformin interfere with exercise?
It has been reported to attenuate some mitochondrial and cardiorespiratory adaptations to training in older adults. If confirmed, that is a direct trade-off against one of the best-evidenced interventions available.
Which agents have the strongest human outcome data?
Approved metabolic and cardiovascular drugs tested for cardiovascular and kidney endpoints. The compounds marketed most enthusiastically as longevity agents have the least outcome data.
How should I read longevity trial news?
Check the phase and participant count, whether the endpoint was a biomarker or an outcome, whether there was a control group, and whether the source is a peer-reviewed paper or a press release.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.